tradmap

INBX Earnings Inhibrx Biosciences, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$20 $46 $113 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $900000 $2M 2023 2024 2025
Revenue
Net income (annual)
-$241M $723M $2B $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$13 $55 $123 $0 Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $817000 $2M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$94M $882M $2B $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–13 of 13
Q2 20262026-06-30-4.492026-08-1310-Q
Q1 20262026-03-31-2.152026-05-1410-Q
FY 20252025-12-31-9.042026-03-1910-K
Q3 20252025-09-30-6.932025-11-1410-Q
Q2 20262025-06-30-4.652026-08-1310-Q
Q1 20262025-03-31-2.802026-05-1410-Q
FY 20252024-12-31112.622026-03-1910-K
Q3 20252024-09-30117.092025-11-1410-Q
Q2 20252024-06-30122.752025-08-1310-Q
Q1 20252024-03-31-5.772025-05-1410-Q
FY 20242023-12-31-20.482025-03-1710-K
Q3 20242023-09-30-13.192024-11-1410-Q
Q2 20242023-06-30-8.802024-08-1310-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.